R&D spending by the top 25 Indian pharmaceutical companies rose 28.8% to INR 9,250 crore ($1.4 billion) for the year ending March 2015. Sales as a percentage of revenues rose from 6.6% to 7.0%. The top three R&D spenders were Sun Pharmaceutical Industries, whose expenditures rose 87.0% to INR 1,856 crore; Dr. Reddy’s Laboratories, whose spending grew 33.4% to INR 1,685 crore; and Lupin, whose spending increased 16.8% to INR 1,118 crore. Other companies recording growth in R&D spending of more than 30% were Aurobindo Pharma, Biocon and Sun Pharmaceutical Advanced Research. For the first nine months of the year, 113 Abbreviated New Drug Applications from Indian companies received US FDA approval, versus 122 for all of 2014.

Source: Pharmabiz.com